-
Mashup Score: 0Linvoseltamab Plus Carfilzomib Achieves Deep, Durable Responses for Triple-Class Exposed Multiple Myeloma - 11 day(s) ago
Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of linvoseltamab plus carfilzomib for patients with heavily pretreated relapsed/refractory multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
According to results from the TROPION-Lung02 study, datopotamab deruxtecan plus pembrolizumab both with and without the addition of platinum-based chemotherapy demonstrated promising durability and safety among patients with advanced non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the #TROPIONLung02 study, #DatoDXd plus #pembrolizumab with and without platinum-based chemotherapy demonstrated promising durability and safety among patients with advanced #NSCLC. Learn more: https://t.co/okokOI4MZX #medtwitter #onctwitter https://t.co/UjXFcNpIUe
-
-
Mashup Score: 0Home - 12 day(s) ago
Intended Learners The proposed activity is intended for community and academic oncology healthcare professionals (HCPs) who care for patients with EP-NECs, including oncologists, gynecologic oncologists, gastrointestinal oncologists, oncology nurse practitioners (NPs) and physician assistants (PAs), radiologists, pathologists, and pharmacists; as well as allied HCPs who care for patients with EP-NECs. Learning Objectives Delineate the key differences between NETs and NECs, including their respective
Source: hmp-global.swoogo.comCategories: General Medicine NewsTweet-
From biomarker-driven strategies to cutting-edge trial data, this live webinar provides the clinical updates you need to deliver informed care. Led by Dr. Jonathon Strosberg and Dr. Namrata Vijayvergia. 📅 June 23 or June 26 | 1.0 CE/CME 🔗 Register now: https://t.co/XlpwwLZaEz https://t.co/VlIxMl595Y
-
-
Mashup Score: 0Chromosome 1q Abnormalities Associated With Worse Survival Outcomes Among Patients With Newly Diagnosed Multiple Myeloma - 12 day(s) ago
Among patients with newly diagnosed multiple myeloma, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Among patients with newly diagnosed #MM, abnormalities of chromosome 1q were associated with inferior survival outcomes and other high-risk cytogenetic feature, according to data presented at the 2025 ASCO Annual Meeting. Learn more: https://t.co/yRvrVnk0ct https://t.co/YQ4HAaHkwM
-
-
Mashup Score: 0
According to results from a phase 2 dose-expansion study, 30 mg of ZG006 is preferable to 10 mg among patients with advanced small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from a phase 2 dose-expansion study, 30 mg of #ZG006 is preferable to 10 mg among patients with advanced #SCLC. Learn more: https://t.co/HMrUVONTT5 #medtwitter #onctwitter https://t.co/jfdxtRtoQC
-
-
Mashup Score: 0Olutasidenib Shows Improved Efficacy in Earlier Lines of Therapy for R/R IDH1-Mutant AML - 13 day(s) ago
Among patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Among patients with relapsed/refractory IDH1-mutant #AML, #olutasidenib demonstrates improved response and survival outcomes when used earlier in treatment sequence. Learn more: https://t.co/QiKu6N41SY https://t.co/58UNK723CC
-
-
Mashup Score: 0Evaluating Zilovertamab Vedotin Plus R-CHOP as Frontline Therapy for Patients With DLBCL: waveLINE-010 - 14 day(s) ago
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of diffuse large B-cell lymphoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Russell Gollard, MD discusses the waveLINE-010 study assessing the efficacy and safety of #zilovertamab vedotin plus rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of #DLBCL. Learn more: https://t.co/91bWGzJKuU https://t.co/nDiEo5hd2E
-
-
Mashup Score: 0Ribociclib Plus Endocrine Therapy Lacks Cost-Effectiveness in HR-Positive, HER2-Negative Early Breast Cancer - 14 day(s) ago
Kunal Potnis, MD, shares an analysis of the cost-effectiveness of ribociclib plus endocrine therapy compared to endocrine therapy alone among patients with HR-positive, HER2-negative early breast cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Kunal Potnis, MD, discusses an analysis of the cost-effectiveness of #ribociclib plus endocrine therapy compared to endocrine therapy alone among patients with HR-positive, HER2-negative early breast cancer. Learn more: https://t.co/2RwsJ5yDBK #medtwitter #onctwitter https://t.co/RJU8wEQtyo
-
-
Mashup Score: 0CARTITUDE-1: Ciltacabtagene Autoleucel Demonstrates Durable Long-Term Remission in R/R MM - 15 day(s) ago
Peter Voorhees, MD, discusses long-term results from the CARTITDE-1 trial, which demonstrated durable and deep responses at 5 years following ciltacabtagene autoleucel infusion among patients with heavily pretreated relapsed/refractory MM.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Peter Voorhees, MD, discusses long-term results from the CARTITDE-1 trial, which demonstrated durable and deep responses at 5 years following #ciltacabtagene autoleucel infusion among patients with heavily pretreated relapsed/refractory #MM. Learn more: https://t.co/wpLHGrytqB https://t.co/CNzUAvnlZ0
-
-
Mashup Score: 0Omission of Carboplatin from Neoadjuvant Therapy Demonstrates Promise for Patients With HER2-Positive Early Breast Cancer - 15 day(s) ago
According to results from the phase 3 neoCARHP trial, de-escalated neoadjuvant taxane therapy plus trastuzumab and pertuzumab without the addition of carboplatin demonstrated promise in HER2-positive early breast cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the phase 3 #neoCARHP trial, de-escalated neoadjuvant taxane therapy plus #trastuzumab and #pertuzumab without the addition of #carboplatin demonstrated promise in #HER2-positive early breast cancer. Learn more: https://t.co/pkvGYJHWnS https://t.co/o36l1CzoO4
-
Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of #linvoseltamab plus #carfilzomib for patients with heavily pretreated relapsed/refractory #MM. Learn more: https://t.co/8EjSDKx4GP https://t.co/DiOL1XMbM2